Приложение 13. Библиография

1. Баркаган З.С. Геморрагические заболевания и синдромы. М.: Медицина, 1988, с. 160-214.

2. Баркаган З.С., Момот А.П. Диагностика и контролируемая терапия нарушений гемостаза. М.: Ньюдиамед, 2001, с. 70-117.

3. Воробьев А.И. Руководство по гематологии. М.: Медицина, 1985, т. 2, с. 229-251.

4. Воробьев А.И. Руководство по гематологии. М.: Ньюдиамед, 2005.

5. Лопатина Е.Г., Плющ О.П., Копылов К.Г., Кудрявцева Л.М. Оценка показателя "качество жизни" у взрослых больных гемофилией, находящихся на "домашнем лечении" // Новое в трансфузиологии, 2004, N 39, с. 5-16 (Москва).

6. Проблемы гематологии и переливания крови, 2003, 2, с. 5-11 (Москва).

7. Плющ О.П., Копылов К.Г. Амбулаторное лечение больных гемофилией и болезнью Виллебранда // Гематол. и трансфузиол., 2002, с. 30-34 (Москва).

8. Плющ О.П., Копылов К.Г., Лопатина Е.Г., Северова Т.В., Атауллаханов Ф.И. Домашнее лечение концентратом фактора МП больных гемофилией А.

9. Плющ О.П., Хаметова Р.Н., Лихачева Е.А. Диагностика, амбулаторное лечение и профилактика больных гемофилией. Методические рекомендации. М., 1989, с. 1-25.

10. Aledort L.M. Comparative thrombotic event incidence after infusion of recombinant factor Vila versus factor VIII inhibitor bypass activity // Thromb. Haemost., 2004, 2. P. 1700-1708.

11. Brackmann H.H., Oldenburg J., Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years of the Bonn Protocol. Vox Sang, 1996; 70 (Suppl.). P. 30-35.

12. Bray et al. Multicenter study of recombinant Factor VIM: safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. // Blood, 1994; 83 (9). P. 2428-2435.

13. Carol K. Kasper. Diagnosis and management of ingibitor to factor VIII and IX. An introductory discussion for physicians. World Federation of Hemophilia 2004, 34.

14. Dasani H. et al. Long term follow-up of patients treated with BPL 8Y Factor VIII concentrate at one centre. World Federation of Haemophilia, Dublin 23-28 June 1996. P. 24 (Abstract 90).

15. Donna M. DiMichele Ingibitors in hemophilia: Primer World Federation of Hemophilia 2004, 7.

16. Ehrlich H.J., Henzl M.J., Gomperts E.D. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events // Haemophilia, 2002, 8. P. 83-90.

17. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin. // Thromb. Haemost., 2000, Vol. 26 (4). P. 385-391.

18. Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in Hemopilia treatment in 2000. Semin // Thromb. Haemost., 2000, Vol. 26 (4). P. 363-366.

19. Hilgartner M., Makipernaa, Dimichele D.M. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease // Haemophilia, 2003, 9. P. 261-268.

20. Hvid I. and Rodriguez-Merchan E.C. Orthopaedic surgery in haemophilic patients with inhibitors: an overview // Haemophilia, 2002, 8. P. 288-291.

21. Ingerslev I. Hemophilia. Strategies for the treatment of inhibitor patients // Haematologica, 2000 Oct., 85 (S. 10). P. 15-20.

22. Kasper С.К., Costa e Silva M. Registry of Clotting Factor Concentrates. World Federation of Hemophilia (January 2004).

23. Kasper C.K. Lusber J.M. Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion, 1993 May, Vol. 33. P. 422-434.

24. Lee Ch. Recombinant cloting factors in the treatment of hemophilia // Thromb. Haemost., August-1999, Vol. 82, N 2, P. 516-524.

25. Ljung R. Prophylactic infusion. Regimens in the menagement of hemophilia // Thromb. Haemost., 1999, 82 (2), с 525-530.

26. Lloyd M., Wicht Y., Paisley S. and Knight. Control of bleeding in patient with inhibitors: a systematic review // Haemophilia, 2003, 9. P. 464-529.

27. Lusher et al. Recombinant Factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy and development of inhibitors // New Engl. J. Med., 1993, 328. P. 453-459.

28. Lusher J.M., Roberts H.R., Davignon G., Joist J.H., Smith H., Shapiro A. et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group // Haemophilia, 1998, 4 (6), с 790-798.

29. McPherson J., league L., Lloyd J., Jupe D., Rowell J., Ockelford P. et al. Experience with recombinant factor VIIa // Australia and New Zealand Haemostasis, 1996, 26 (Suppl. 1). P. 109-117.

30. Medgyessy L., Petra O., Elodi S. Long-term surveillance of haemophilia A patients treated with a high-purity plasma derived facto l'VIM concentrate // Haemophilia, 2002, 8, 572, 20 PO11.

31. Negrier C, Goudemand J., Sultan Y., Bertrand M., Rothschild C, Lauroua P. Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX inhibitors // Thromb. Haemost., 1997, 77. P. 1113-1119.

32. Negrier C., Hay C.R.M. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin // Thromb. Hemost., 2000, Vol. 26 (4). P. 407-412.

33. Negrier C., Roblet S., Koppers K., Bagot d'Arc M. and Calvora R. Multicentre prospective survey on the use of FEIBA in France in patients with factor VIII and factor IX inhibitors. Paris XVIII Congress of the International Society on Thrombosis and Haemostasis 2001 (congress abstract).

34. Nilsson I.M. Biochemical properties of factor VIII, factor IX and von Willebrand factor. Hemophilia. Pharmacia. Plasma Products, 1994. P. 8-10.

35. Quintana-Molina M., Martinez-Bahamonde F., Gonzalez-Garcia E, Romero-Garrido J., Camacho A.. Jimenez-Yuste V., Fernandez-Bello I., Hernandez-Navarro F. Surgery in haemophilic patients with inhibitor: 20 years of experience // Haemophilia. 2004, 10 (Suppl. 2). P. 30-40.

36. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing // Haemophilia, 2004, 10 (2). P. 169-173.

37. Santagostino E., Gringeri A., Mannucci P.M. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention // Brit. J. Haematol., 1999, 104 (1). P. 22-26.

38. Scharrer I., Brey G.L., Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates // Haemophilia. 1999, 5 (3), с 145-154.

39. Scharrer I., on behalf of the German NovoSeven Study Group. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency // Haemophilia, 1999, 5. P. 253-259.

40. Stephen A. Mayer, Nikolai C. Brune, Kamilla Begtrup et al. Recombinant Activated Factor VIII for Acute Intracerebral Hemorrhage Trial Investigators // N. Engl. J. Med., 2005, 352. P. 777-785.

41. Tjonnfjord G.E., Brinch L., Brosstad F., Evensen S.A. The Norwegian experience with FEIBAR as first choice in surgery for patients with inhibitors 1996-2001 // Haemophilia. 2002, 8. P. 545-546.

42.Turecek P.L., Varadi K., Keil В.. Negrier C., Berntorp E., Astermark J., Bordet J.С., Morfini M., Linari S., Schwarz H.P. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol // Haemost. Thromb. 2003, 33, 1. P. 16-22.

43. Varadi K., Turecek P.L., Schwarz H.P. Thrombin generation assay and other universal tests for monitoring haemophilia therapy//Haemophilia, 2004, 10 (Suppl. 2). P. 17-21.

44. Wolf D.M. et al. Clinical efficacy safety and pharmacokinetic properties of the factor VIII concentrate Haemoctiiv SDH in previously treated patients with severe haemophilia A. // Haemophilia, 2004, 10. P. 1-11.